Related Experiment Videos
Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk
J M Van den Hout1, A J Reuser, J B de Klerk
1Department of Pediatrics, Sophia Children's Hospital, University Hospital Rotterdam, The Netherlands. vanderploeg@alkg.azr.nl
Insights
Enzyme therapy using recombinant human alpha-glucosidase shows promising results for infantile Pompe disease. Treatment improved cardiac function, motor skills, and normalized enzyme activity, indicating potential for this metabolic myopathy treatment.
Area of Science:
- Biochemistry
- Genetics
- Pediatrics
Background:
- Pompe disease is a rare metabolic myopathy.
- It is caused by a deficiency in the enzyme acid alpha-glucosidase.
- This deficiency leads to progressive muscle damage.
Purpose of the Study:
- To evaluate the safety and efficacy of enzyme replacement therapy (ERT) for infantile Pompe disease.
- To assess the impact of recombinant human alpha-glucosidase on clinical outcomes.
- To investigate the biochemical and histological effects of ERT.
Main Methods:
- A clinical study involving four infants with Pompe disease.
- Administration of recombinant human alpha-glucosidase derived from transgenic rabbit milk.
- Monitoring of enzyme activity, clinical status, cardiac function (LVMI), and skeletal muscle histology over 36 weeks.
Main Results:
- The enzyme therapy was generally well tolerated.
- Recombinant human alpha-glucosidase reached target tissues, including skeletal muscle.
- Normalization of acid alpha-glucosidase activity in skeletal muscle and degradation of PAS-positive material were observed.
- Significant improvement in cardiac function, notably a reduction in left ventricular mass index (LVMI).
- Enhanced motor function and overall clinical improvement in all patients.
Conclusions:
- Enzyme replacement therapy with recombinant human alpha-glucosidase is a safe and effective treatment for infantile Pompe disease.
- The therapy demonstrates significant positive effects on cardiac and motor function.
- These preliminary findings support further development and extension of enzyme therapy for Pompe disease.
Abstract:
Pompe disease is a metabolic myopathy caused by deficiency of lysosomal acid alpha-glucosidase. In this report we review the first 36 weeks of a clinical study on the safety and efficacy of enzyme therapy aimed at correcting the deficiency. Four patients with infantile Pompe disease were enrolled. They received recombinant human alpha-glucosidase from transgenic rabbit milk. The product is generally well tolerated and reaches the primary target tissues. Normalization of alpha-glucosidase activity in skeletal muscle was obtained and degradation of PAS-positive material was seen in tissue sections. The clinical condition of all patients improved. The effect on heart was most significant, with an impressive reduction of the left ventricular mass index (LVMI). Motor function improved. The positive preliminary results stimulate continuation and extension of efforts towards the realization of enzyme therapy for Pompe disease.